Ligand Acquires Royalty And Milestone Interest In Santen’s Ryjunea From Sydnexis For $23 Million

Sept 22 (Reuters) - Ligand Pharmaceuticals Incorporated LGND.O:

• LIGAND ACQUIRES ROYALTY AND MILESTONE INTEREST IN SANTEN’S RYJUNEA® FROM SYDNEXIS FOR $23 MILLION

• LIGAND PHARMACEUTICALS INCORPORATED - TO RECEIVE TIERED ROYALTY ON RYJUNEA NET SALES IN EMEA

• LIGAND PHARMACEUTICALS INCORPORATED - BUYS RIGHTS TO ROYALTY AND MILESTONE PAYMENTS ON RYJUNEA IN EMEA

• LIGAND PHARMACEUTICALS INCORPORATED: ACQUIRED PAYMENT RIGHTS INCLUDE A TIERED LOW-DOUBLE-DIGIT TO HIGH-TEENS ROYALTY ON RYJUNEA NET SALES IN EMEA

Further company coverage: LGND.O